MCL-1 inhibitors such as AZD5991 (NCT0321868), S64315 (NCT0297936), AMG176 (NCT0267545), and AMG397 (NCT03465540) are under evaluation in phase 1 clinical trials for AML patients. The gene discussed is MCL1; the disease is acute myeloid leukemia.